We’re proud to be part of such a tight-knit community. The more we can stay in touch, the closer we can work together. Click subscribe to receive news and updates about Amylyx.
A Phase 1, Multicenter, Randomized, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of AMX0114 in ALS (LUMINA)
Lead Author: Sabrina Paganoni, MD, PhD
Published: The Canadian Neurological Sciences Federation (CNSF) Congress
Date: June 11, 2025
Survival Results from the Global Phase 3 Trial (PHOENIX) Evaluating Sodium Phenylbutyrate and Ursodoxicoltaurine in ALS
Lead Author: Leonard H. van den Berg, MD, PhD (Presenter)
Published: European Network to Cure ALS (ENCALS) 2025 Meeting
Date: June 5, 2025
48-Week Results from the HELIOS Trial: A Phase 2, Open-Label Study Evaluating an Oral, Fixed-Dose Combination of Sodium Phenylbutyrate and Taurursodiol in Wolfram Syndrome
Lead Author: Fumihiko Urano, MD, PhD
Published: Joint Congress of the European Society for Pediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE)
Date: May 12, 2025
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Avexitide in Post-Bariatric Hypoglycemia (LUCIDITY)
Lead Author: Ryan Miller, MD
Published: World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
Date: December 12, 2024
Amylyx Update on Development of AMX0114, an Antisense Oligonucleotide Targeting Calpain-2
Lead Author: Lauren Kett, MD, PhD (Presenter)
Published: ALS ONE’s 7th Annual ALS Research Symposium
Date: November 14, 2024
Results from the HELIOS Trial: A Phase 2 Open-Label Study Evaluating an Oral, Fixed-Dose Combination of Sodium Phenylbutyrate and Taurursodiol in Wolfram Syndrome
Lead Author: Amy Viehoever, MD, PhD (Presenter)
Published: Child Neurology Society Annual Meeting
Date: November 11 - 14, 2024
A Phase 1, Multicenter, Randomized, Placebo-Controlled Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of AMX0114 in Amyotrophic Lateral Sclerosis (LUMINA)
Lead Author: Lauren Kett, MD, PhD (Presenter)
Published: Northeast ALS Consortium (NEALS) Annual Meeting
Date: October 23, 2024
Results from the Phase 2, Open-Label Study Evaluating an Oral, Fixed-Dose Combination of Sodium Phenylbutyrate and Taurursodiol (PB&TURSO) in Wolfram Syndrome
Lead Author: Nathalie Erpelding, PhD (Presenter)
Published: 9th International Wolfram Syndrome Symposium
Date: October 23, 2024
Results from A Phase 2, Open-Label Study Evaluating an Oral, Fixed-Dose Combination of Sodium Phenylbutyrate and Taurursodiol (PB&TURSO) in Wolfram Syndrome (HELIOS)
Lead Author: Lahar Mehta, MD (Presenter)
Published: International Society for Pediatric and Adolescent Diabetes (ISPAD) 50th Annual Congress
Date: October 17, 2024
ORION: A Global Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled Trial of AMX0035 in Progressive Supranuclear Palsy (A35-009)
Lead Author: Anne-Marie Wills, MD
Published: International Parkinson and Movement Disorder Society
Date: October 1, 2024